Literature DB >> 10078723

Abnormal performance on the PD test battery by asymptomatic first-degree relatives.

E B Montgomery1, K B Baker, K Lyons, W C Koller.   

Abstract

OBJECTIVE: To determine whether a sensitive and specific battery of tests (PD Battery) could identify a subset of asymptomatic first-degree relatives (FDRs) of PD patients who were significantly more impaired than age-matched normal control (NC) subjects. The PD Battery incorporates tests of motor function, olfaction, and mood. In previous studies, it has shown high specificity and sensitivity in distinguishing mildly affected PD patients from NC subjects.
METHODS: The PD Battery and regression analysis-derived scoring equations were applied to asymptomatic FDRs.
RESULTS: Eighty FDRs and 100 NC subjects were tested. Of the FDRs, 22.5% scored in the abnormal range, and 9% of NC subjects had abnormal scores. This difference was statistically significant. Further analysis demonstrated that FDRs with abnormal scores on the PD Battery differed on all three components of the test battery from FDRs who had normal scores. Among the sons and daughters whose scores were abnormal, there was a much higher prevalence of the affected parent being the father.
CONCLUSIONS: The proportion of FDRs who demonstrated abnormal performance on the PD Battery was greater than that of NC subjects. Thus, the PD Battery may detect the asymptomatic carrier state or risk for PD. Sons and daughters whose scores were in the abnormal range were more likely to have fathers with PD.

Entities:  

Mesh:

Year:  1999        PMID: 10078723     DOI: 10.1212/wnl.52.4.757

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

1.  Multiple step pattern as a biomarker in Parkinson disease.

Authors:  Tanya Blekher; Marjorie Weaver; Jason Rupp; William C Nichols; Siu L Hui; Jacqueline Gray; Robert D Yee; Joanne Wojcieszek; Tatiana Foroud
Journal:  Parkinsonism Relat Disord       Date:  2009-02-10       Impact factor: 4.891

2.  ELECTRONIC PLATFORM MEASURES OF BALANCE IMPAIRMENT IN PARKINSONIANS AND FIRST DEGREE RELATIVES.

Authors:  Gregory M Constantine; Nicolaas I Bohnen; Carson C Chow
Journal:  Int J Pure Appl Math       Date:  2004

3.  Predictive models of postural control based on electronic force platform measures in patients with Parkinson's disease.

Authors:  Gregory M Constantine; Marius G Buliga; Larry S Ivanco; Robert Y Moore; Nicolaas I Bohnen
Journal:  Int J Appl Math (Sofia)       Date:  2005

Review 4.  Preclinical diagnosis of Parkinson's disease: are we there yet?

Authors:  Andrew Siderowf; Matthew B Stern
Journal:  Curr Neurol Neurosci Rep       Date:  2006-07       Impact factor: 5.081

Review 5.  Olfaction in Parkinson's disease and related disorders.

Authors:  Richard L Doty
Journal:  Neurobiol Dis       Date:  2011-12-20       Impact factor: 5.996

Review 6.  Early Parkinson's disease and non-motor issues.

Authors:  K Ray Chaudhuri; Yogini Naidu
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

7.  Olfactory deficits in mice overexpressing human wildtype alpha-synuclein.

Authors:  Sheila M Fleming; Nicole A Tetreault; Caitlin K Mulligan; Ché B Hutson; Eliezer Masliah; Marie-Françoise Chesselet
Journal:  Eur J Neurosci       Date:  2008-07       Impact factor: 3.386

Review 8.  Olfactory dysfunction in Parkinson disease.

Authors:  Richard L Doty
Journal:  Nat Rev Neurol       Date:  2012-05-15       Impact factor: 42.937

9.  Identification of key uric acid synthesis pathway in a unique mutant silkworm Bombyx mori model of Parkinson's disease.

Authors:  Hiroko Tabunoki; Hiromasa Ono; Hiroaki Ode; Kazuhiro Ishikawa; Natsuki Kawana; Yutaka Banno; Toru Shimada; Yuki Nakamura; Kimiko Yamamoto; Jun-Ichi Satoh; Hidemasa Bono
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

10.  Olfactory deficits in an alpha-synuclein fly model of Parkinson's disease.

Authors:  Alex Y Chen; Shouzhen Xia; Paul Wilburn; Tim Tully
Journal:  PLoS One       Date:  2014-05-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.